Publications by authors named "Helena Bote de Cabo"
Article Synopsis
- KRAS mutations are common in non-small-cell lung cancer (NSCLC), making this a diverse group of cancers that respond differently to therapies compared to other types of cancer.
- Despite being considered "undruggable" for years, new direct KRAS inhibitors like sotorasib and adagrasib have gained FDA approval, revolutionizing treatment options for patients with previously treated KRAS-mutated NSCLC.
- While these inhibitors mark a major advancement, they are not curative and resistance mechanisms need to be understood, prompting ongoing research into new inhibitors and combination therapies, including those with immune checkpoint inhibitors.
Immune checkpoint inhibitors (ICIs) have revolutionized the management of non-oncogene addicted non-small-cell lung cancer (NSCLC). Blocking the anti-PD-1 axis represents the current standard of care in the first-line setting, with drugs administered either as monotherapy or in combination with chemotherapy. Despite notable successes achieved with ICIs, most of their long-term benefits are restricted to approximately 20% of patients.
View Article and Find Full Text PDFBackground And Objective: This narrative review is intended to provide pragmatic knowledge of current methods for the search of anaplastic lymphoma kinase () fusions in patients with non-small cell lung carcinoma (NSCLC). This information is very timely, because a recent survey has identified that almost 50% of patients with advanced NSCLC were not candidates for targeted therapies because of biomarker testing issues.
Methods: PubMed was searched from January 1, 2012 to February 28, 2023 using the following keywords: "" and "lung", including reviews and our own work.
Precision oncology comprises the set of strategies that aim to design the best cancer treatment based on tumor biology. A recognized subset of patients with non-small cell lung cancer (NSCLC) harbor actionable genomic aberrations that can benefit from targeted therapy. In lung cancer, epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements are well characterized oncogenic drivers for which the therapeutic use of tyrosine kinase inhibitors has demonstrated improved outcomes compared with chemotherapy.
View Article and Find Full Text PDF